Home › NDC Lookup › RxCUI directory › RxCUI 1356580

Perampanel 8 MG Oral Tablet [FYCOMPA] — RxCUI 1356580

RxNorm drug concept · Semantic branded drug
RxCUI 1356580 Semantic branded drug · SBD ● Current RxNorm concept 14 FDA products 30 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1356580
Official namePerampanel 8 MG Oral Tablet [FYCOMPA]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFycompa 8 MG Oral Tablet
FDA products mapped14
Package NDCs mapped30
Reported Medicaid activity (SDUD)63,501 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Perampanel: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Perampanel is a seizure medicine used to treat two types of epilepsy: partial-onset seizures (seizures that start in one part of the brain) and primary generalized tonic-clonic sei...
  • What is perampanel actually for — why did my doctor prescribe it?
  • Taking perampanel at bedtime is intentional — it causes dizziness and drowsiness in many people, and sleeping through the worst of that makes it much easier to tolerate. It also he...
  • Why do I have to take it at bedtime? Can I take it at a different time?
📖 Read our full Perampanel guide →

🕸️ Concept Web — How Perampanel 8 MG Oral Tablet [FYCOMPA] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Perampanel 8 MG Oral Tablet [FYCOMPA] RxCUI 1356580

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Perampanel 1356552
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • FYCOMPA 1356558
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Perampanel Oral Tablet 1356556
    • Perampanel Oral Product 1356554
    • Perampanel Pill 1356555
    • Perampanel Oral Tablet [FYCOMPA] 1356560
    • FYCOMPA Oral Product 1356561
    • FYCOMPA Pill 1356562
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Perampanel 8 MG Oral Tablet SCD · 1356578
  • Perampanel 8 MG SCDC · 1356577
  • Perampanel Oral Tablet SCDF · 1356556
  • Perampanel Oral Product SCDG · 1356554
  • Perampanel Pill SCDG · 1356555

Brand-Name Concepts

  • Perampanel 8 MG [FYCOMPA] SBDC · 1356579
  • Perampanel Oral Tablet [FYCOMPA] SBDF · 1356560
  • FYCOMPA Oral Product SBDG · 1356561
  • FYCOMPA Pill SBDG · 1356562
  • FYCOMPA BN · 1356558

📦 FDA Products & Package NDCs

14 products · 30 package NDCs
30 package NDCs map to RxCUI 1356580 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
62856-0272-14 14 TABLET in 1 PACKET (62856-272-14) Fycompa Eisai Inc. 2018-08-08
62856-0272-30 30 TABLET in 1 BOTTLE (62856-272-30) Fycompa Eisai Inc. 2012-10-22
62856-0272-90 90 TABLET in 1 BOTTLE (62856-272-90) Fycompa Eisai Inc. 2012-10-22
62856-0274-14 14 TABLET in 1 PACKET (62856-274-14) Fycompa Eisai Inc. 2018-08-08
62856-0274-30 30 TABLET in 1 BOTTLE (62856-274-30) Fycompa Eisai Inc. 2012-10-22
62856-0274-90 90 TABLET in 1 BOTTLE (62856-274-90) Fycompa Eisai Inc. 2012-10-22
62856-0276-30 30 TABLET in 1 BOTTLE (62856-276-30) Fycompa Eisai Inc. 2012-10-22
62856-0276-90 90 TABLET in 1 BOTTLE (62856-276-90) Fycompa Eisai Inc. 2012-10-22
62856-0278-30 30 TABLET in 1 BOTTLE (62856-278-30) Fycompa Eisai Inc. 2012-10-22
62856-0278-90 90 TABLET in 1 BOTTLE (62856-278-90) Fycompa Eisai Inc. 2012-10-22
62856-0280-30 30 TABLET in 1 BOTTLE (62856-280-30) Fycompa Eisai Inc. 2012-10-22
62856-0280-90 90 TABLET in 1 BOTTLE (62856-280-90) Fycompa Eisai Inc. 2012-10-22
62856-0282-30 30 TABLET in 1 BOTTLE (62856-282-30) Fycompa Eisai Inc. 2012-10-22
62856-0282-90 90 TABLET in 1 BOTTLE (62856-282-90) Fycompa Eisai Inc. 2012-10-22
62856-0290-38 340 mL in 1 BOTTLE (62856-290-38) Fycompa Eisai Inc. 2016-04-30
69616-0272-14 14 TABLET in 1 PACKAGE (69616-272-14) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0272-30 30 TABLET in 1 BOTTLE (69616-272-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0272-90 90 TABLET in 1 BOTTLE (69616-272-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0274-14 14 TABLET in 1 PACKAGE (69616-274-14) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0274-30 30 TABLET in 1 BOTTLE (69616-274-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0274-90 90 TABLET in 1 BOTTLE (69616-274-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0276-30 30 TABLET in 1 BOTTLE (69616-276-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0276-90 90 TABLET in 1 BOTTLE (69616-276-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0278-30 30 TABLET in 1 BOTTLE (69616-278-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0278-90 90 TABLET in 1 BOTTLE (69616-278-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0280-30 30 TABLET in 1 BOTTLE (69616-280-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0280-90 90 TABLET in 1 BOTTLE (69616-280-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0282-30 30 TABLET in 1 BOTTLE (69616-282-30) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0282-90 90 TABLET in 1 BOTTLE (69616-282-90) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
69616-0290-38 340 mL in 1 BOTTLE (69616-290-38) Fycompa Catalyst Pharmaceuticals, Inc. 2024-01-02
Observed labelers: Catalyst Pharmaceuticals, Inc. (15) · Eisai Inc. (15) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.